AAOS Comments on Request for Information for Episode-Based Payment Model

Last week the American Association of Orthopaedic Surgeons (AAOS) submitted comments to the Center for Medicare and Medicaid Innovation (CMMI) in response to a request for information they released in July regarding the development of Episode-Based Payment Models (CMS-5540-NC).

In its letter, AAOS expressed their support for engaging physicians in the design and implementation of alternative payment models and urged the Centers for Medicare & Medicaid Services (CMS) to consider the impact that interoperability, multi-payer alignment of measures, and administrative burden have on the ability of physicians to successfully participate in alternative payment models.

As a thought leader in reducing the complexities of value-based care and as clinical experts delivering high-value, patient-centered musculoskeletal care, AAOS shared their insights and recommendations which include:

Expanding alternative payment model (APM) episodes beyond 30 days, and encouraging the agency to consider episodes longer than 90 days
Only considering voluntary models with participation incentives– as a mandatory model would be in the disinterest of collaborative, patient-centered care
Ensuring that barriers, such as interoperability, multi-payer alignment of measures, and administrative burden are resolved in future models
Finding an approach that allows downstream risk sharing with orthopaedic surgeons
Exploring a pilot program for the management of chronic and prevalent conditions by orthopaedic surgeons

In July, AAOS and several physician organizations, requested an extension to the proposal’s 30-day comment period. While the request was denied by CMMI, the agency agreed to meet with AAOS for further discussions.

“The AAOS is excited to partner with CMS and offer our expertise based on our extensive experience with the design, implementation, and evaluation of value-based payment models. As leaders in payment model transformation, the AAOS is well-positioned to ensure that changes to the way hospitals and physicians are paid for their services ultimately provides value to Medicare beneficiaries and their families, while reducing the administrative burden on the healthcare system,” wrote AAOS President Kevin J. Bozic, MD, MBA, FAAOS.

Read the full letter here.

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”